Mesoblast Limited Appoints Rosa-Bjorkeson COO

Attention Deficit Hyperactivity Disorder: A Drug Can Relieve Persistent Daydreaming, Fatigue, and Brain Sluggishness in Adults

Researchers at NYU Grossman School of Medicine and Icahn School of Medicine at Mount Sinai who led the study say the stimulant lisdexamfetamine (sold as Vyvanse) reduced by 30 percent self-reported symptoms of sluggish cognitive tempo. It also lowered by over 40 percent symptoms of ADHD and significantly corrected deficits in executive brain function, with fewer episodes of procrastination, improvements in keeping things in mind, and strengthened prioritization skills.

Lucida Medical (Cambridge University Spin-out) Joins GE Healthcare Edison™ Accelerator Programme

Lucida Medical was invited to join the Edison Accelerator programme for its pioneering work in helping identify prostate cancer and its exceptional development team led by Prof Evis Sala and Dr Antony Rix, both highly experienced in artificial intelligence, or AI, medical technology.

Ms. Rosa-Bjorkeson will manage Mesoblast’s commercial operations, leading the business units, building out key strategic alliances, and overseeing product launches.

She will be part of an expanded executive leadership structure that will deliver deep operational, commercial, and strategic pharmaceutical experience in line with the Company’s transition to becoming a fully integrated commercial organization.

Mesoblast Chief Executive Dr. Silviu Itescu stated: “I am pleased to welcome Ms Rosa-Bjorkeson to join our highly experienced and credentialed cross-functional executive leadership team. Mesoblast is very well positioned to build out our product portfolio and to be ready for the potential launch of RYONCIL™ in the United States market for pediatric steroid-refractory acute graft versus host disease.”

Ms. Rosa-Bjorkeson has more than 25 years of global experience in the pharmaceutical industry, including executive leadership in corporate and product strategy, market development, and operational execution. She has led multiple successful product launches, including Gilenya® for multiple sclerosis at Novartis where she was Vice President and Head of its multiple sclerosis business unit, Vice President, Business Development and Licensing in the United States, and Country Head and President for Novartis Sweden.

More recently, Ms. Rosa-Bjorkeson served as Executive Vice President and President, Biosimilars, at Baxalta, now a wholly-owned subsidiary of Takeda Pharmaceutical Company. She was also Executive Vice President and Chief Strategy and Development Officer at Mallinckrodt Pharmaceuticals. Ms. Rosa-Bjorkeson is highly valued for her ability to deliver product launch excellence across mass markets, as well as specialty and rare disease brands.

Ms. Rosa-Bjorkeson said: “I am very pleased to join Mesoblast at such an exciting and important time in the Company’s history, and to be part of a cross-functional leadership team that is working towards bringing its cell therapies to patients with critical unmet needs.”





Trinity Health Names Mark LePage, M.D., as Senior Vice President of Medical Groups and Ambulatory Strategy

Prior to his time at IHA, LePage served as chief medical officer of Marshfield Clinic in Wisconsin

Jody Crane, MD Recognized by Modern Healthcare As One of the 50 Most Influential Clinical Executives

Dr. Crane’s work to streamline operations positioned and prepared TeamHealth and its clinicians to face the COVID-19 pandemic. Under Dr. Crane’s leadership, TeamHealth was able to maintain high levels of clinical quality throughout the rapidly changing COVID environment.

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

Subscribe to Medical Device News Magazine here.

Related Articles